Market Place
Sourcing Support
NPPA Exempts Intas Pharma`s Antipsychotic from DPCO for 5 Years
01 Apr 2026 //
PHARMABIZ
Bio-Thera Expands Intas Pharma Partnership for BAT2506
23 Mar 2026 //
PR NEWSWIRE
MDC Recommend 5-Year DPCO Exemption for Intas` Antipsychotic Drug
01 Mar 2026 //
PHARMABIZ
Indian Pharma Market Grew 10.2% YoY In January 2026
17 Feb 2026 //
INDPHARMAPOST
FDA Approves FILKRI, Accord BioPharma`s Biosimilar to NEUPOGEN
17 Feb 2026 //
PR NEWSWIRE
Kashiv Biosciences, Intas Pharma Ink Exclusive Deal For Complex
09 Feb 2026 //
PHARMIWEB
Intas Teams Up With Integrimedical For Needle-Free Injections
29 Dec 2025 //
EXPRESSPHARMA
Finance Ministry Allows 15 Firms To Import Morphine, Codeine
12 Dec 2025 //
PHARMABIZ
Intas & Accord Ink Deal to Buy Prothya Biosolutions
11 Aug 2025 //
PR NEWSWIRE
Accord BioPharma completes UDENYCA franchise acquisition, expands
14 Apr 2025 //
PR NEWSWIRE
Accord BioPharma Marks Over 10,000 Patients Treated With CAMCEVI®
16 Jan 2025 //
PR NEWSWIRE
Coherus Divests UDENYCA® Franchise for $558M to Intas Pharma
03 Dec 2024 //
GLOBENEWSWIRE
Bankruptcy court approves Intas-Shamrock plan for Unimark Remedies
18 Apr 2023 //
ECONOMIC TIMES
Intas` Gujarat, India facility is in the FDA`s crosshairs
20 Jan 2023 //
FIERCE PHARMA
Intas under FDA scrutiny over `cascade of failure` in oversight of GMP documents
19 Jan 2023 //
ENDPTS
Intas Pharma to commercialise Syna Therapeutics’ biosimilar drug LB-0702
02 Nov 2022 //
PHARMABIZ
CCI clears Abu Dhabi Investment Authority`s minority stake buy in Intas Pharma
10 Oct 2022 //
ECONOMIC TIMES
Intas & Dr Reddy`s in race with PEs to buy US` Athenex
05 Aug 2022 //
ECONOMIC TIMES
Prestige Biopharma and Intas Partner to Commercialize Bevacizumab Biosimilar
26 Jul 2022 //
BUSINESSWIRE
Abu Dhabi Sovereign Fund to buy into Intas Pharma
26 Apr 2022 //
ECONOMIC TIMES
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
19 Apr 2022 //
BUSINESSWIRE
Intas, Axantia ink agreement to commercialise Ranibizumab in Middle East
05 Apr 2022 //
HEALTH ET
Intas Pharma signs supply agreement for Ranibizumab biosimilar in Middle East
05 Apr 2022 //
BIOSPECTRUMASIA
Accord Bio, Foresee Pharma Partner to Launch CAMCEVI Injection Emulsion
04 Apr 2022 //
PRNEWSWIRE
NPPA expert panel fixes price for Intas Pharma’s incremental Ig solution
08 Mar 2022 //
PHARMABIZ
J&J back in court over new generic threat from Intas
19 Feb 2022 //
ENDPTS
Indian firm Intas Pharma makes breakthrough in antifungal therapy domain
13 Oct 2021 //
BIOSPECTRUMASIA
Intas enters license agreement with Meiji and Dong commercialize DMB-3115
22 Jul 2021 //
PRNEWSWIRE
Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115
22 Jul 2021 //
EXPRESS PHARMA
Research Finds Babylon Digital-first Model Of Primary Care Lower Significantly
22 Jul 2021 //
PRNEWSWIRE
Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115
22 Jul 2021 //
EXPRESS PHARMA
Research Finds Babylon Digital-first Model Of Primary Care Lower Significantly
22 Jul 2021 //
PRNEWSWIRE
Intas enters license agreement with Meiji and Dong commercialize DMB-3115
22 Jul 2021 //
PRNEWSWIRE
Foresee Enters Exclusive License Agreement with Intas Pharmaceuticals
04 Mar 2021 //
PRNEWSWIRE
Alteogen Enters Into an Exclusive License Agreement With Intas
07 Jan 2021 //
BUSINESSWIRE
Covid-19 fight: Indian companies join race to develop blood products
25 Sep 2020 //
BUSINESS STANDARD
Naari completes acquisition of ANDAs from Intas Pharmaceuticals
11 Jun 2020 //
BIOSPECTRUMASIA
Intas Pharma to donate 2 million hydroxychloroquine tablets for WHO
30 Mar 2020 //
THEHINDUBUSINESSLINE
Advisory issued against retinal disease drug
15 Feb 2019 //
ECONOMIC TIMES
Chrys Capital to buy 10% in Mankind for $350 M
02 Apr 2018 //
BIOSPECTRUM
Former Sanofi and BMS plants in EU reopened by Asian drugmakers
31 Jan 2018 //
FIERCE PHARMA
Intas Pharma slashes cancer drug prices
05 Oct 2017 //
BIOSPECTRUM
Aurobindo Pharma, Intas in race for Teva’s European assets
16 Aug 2017 //
LIVE MINT
Intas eyes Teva’s oncology, women’s health divisions in Europe
10 Aug 2017 //
ECONOMIC TIMES
ChrysCapital sells 3% in Intas to Capital International
03 Apr 2017 //
ECONOMIC TIMES
Indian Drug cos have begun to Adjust to FDA Norms: Intas Pharma
03 Jan 2017 //
MONEY CONTROL
Biologics Enter Top Selling Drugs’ List
29 Dec 2016 //
ECONOMIC TIMES
Aurobindo Pharma may buy Portugal`s Generis, deal likely to be valued at $200M
02 Nov 2016 //
ECONOMIC TIMES
Intas is the dark horse of Indian pharma sector
07 Oct 2016 //
BUSINESS STANDARD
Mitsubishi backs Aurobindo, Intas for Teva asset bid
05 Oct 2016 //
BUSINESS-STANDARD
Aurobindo, Intas in race for $1 billion buyout of Teva UK, submit binding offers
30 Aug 2016 //
ECONOMIC TIMES
Torrent, Intas join fray for teva products in Europe
19 Jul 2016 //
ECONOMIC TIMES
RPG Life Sciences sells biotech business to Intas Pharmaceuticals
25 May 2016 //
BUSINESS STANDARD
Roche sues Intas Pharma over Mircera anaemia drug patent
18 Apr 2016 //
ECONOMIC TIMES
Sanofi Claims Additional Damage in India for its Trademark Plavis
21 Jan 2016 //
TWOFOUR INSIGHT
Sun Pharma in Talks to Acquire Rival Intas
24 Dec 2015 //
PHARMA ASIA
Unimark in talks to sell carbapenen unit
23 Dec 2015 //
FINANCIAL EXPRESS
Drugmakers launch cut-price versions of type 2 diabetes medicine
15 Dec 2015 //
ECONOMIC TIMES
ChrysCap buys 10% stake in research firm GVK Bio
03 Dec 2015 //
ET HEALTHWORLD
